Jostein Dahle
Plus aucun poste en cours
Fortune : 21 121 $ au 31/03/2024
Profil
Jostein Dahle was the founder and had founded Nordic Nanovector ASA in 2009, where he held the title of Chief Scientific Officer.
He also worked as a Director at Oslo universitetssykehus HF.
Dr. Dahle has a doctorate degree from the University of Oslo, which he received in 2000, and a graduate degree from the Norwegian University of Science & Technology, which he received in 1995.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
THOR MEDICAL ASA
0,09% | 31/12/2022 | 212 191 ( 0,09% ) | 21 121 $ | 31/03/2024 |
Anciens postes connus de Jostein Dahle
| Sociétés | Poste | Fin |
|---|---|---|
Oslo universitetssykehus HF
 Oslo universitetssykehus HF Hospital/Nursing ManagementHealth Services Oslo universitetssykehus HF operates local hospital, acute hospitals, and regional hospital for residents and has a number of national tasks. It carries out patient treatment, research, and trial treatments, gives advice and provides education. The company was founded on December 1, 2008 and is headquartered in Oslo, Norway. | Director/Board Member | - |
| THOR MEDICAL | Founder | - |
Formation de Jostein Dahle
| University of Oslo | Doctorate Degree |
| Norwegian University of Science & Technology | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Oslo universitetssykehus HF
Oslo universitetssykehus HF Hospital/Nursing ManagementHealth Services Oslo universitetssykehus HF operates local hospital, acute hospitals, and regional hospital for residents and has a number of national tasks. It carries out patient treatment, research, and trial treatments, gives advice and provides education. The company was founded on December 1, 2008 and is headquartered in Oslo, Norway. | Health Services |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
